Adult Pancreas Transplant Recipient Follow-Up Worksheet

Note: These worksheets are provided to function as a guide to what data will be required in the online TIEDI[®] application. Currently in the worksheet, a red asterisk is displayed by fields that are required, independent of what other data may be provided. Based on data provided through the online TIEDI[®] application, additional fields that are dependent on responses provided in these required fields may become required as well. However, since those fields are not required in every case, they are not marked with a red asterisk.

(
Recipient Information	
Name:	DOB:
SSN:	Gender:
HIC:	Tx Date:
Previous Follow-Up:	Previous Px Stat Date:
Transplant Discharge Date:	
State of Permanent Residence: *	
Zip Code: *	
Provider Information	
Recipient Center:	
Followup Center:	
Physician Name: *	
NPI#:*	
Follow-up Care Provided By: *	OTransplant Center
	Non Transplant Center Specialty Physician
	Oprimary Care Physician
	Other Specify
Specify:	
Donor Information	
UNOS Donor ID #:	
Recovering OPO:	
Donor Type:	
Patient Status	
Date: Last Seen, Retransplanted or Death*	
Patient Status:*	CLIVING
	DEAD
	ORETRANSPLANTED
Primary Cause of Death:	
Specify:	
Contributory Cause of Death:	
Specify:	
Contributory Cause of Death:	
Specify:	
Has the patient been hospitalized since the last patient	
status date: *	
Functional Status: *	
Working for income:*	
Primary Insurance at Follow-up:*	
Specify:	

Copyright © 2022 United Network for Organ Sharing. All rights reserved. OPTN use only. 083022

Clinical Information					
Graft Status: *	Functioning Faile	ed			
If death is indicated for the recipient, report graft status up until the Patient using either oral medication or diet for blood sugar control:	e instance of death.				
Patient on oral medication to control blood sugar?*					
Date of medications resumed: *			ST	=	
Patient using diet to control blood sugar:*					
Patient on insulin?*					
Date insulin resumed: *				ST=	
Average total insulin dosage per day: *		units/kg/day		ST=	
Insulin duration of use: *		days		ST=	
C-peptide value:		ng/mL	ST=		
HbA1c:		%	ST=		
Date of Failure:					
Primary Cause of Graft Failure:					
Other, Specify:					
Contributory causes of graft failure:					
Graft/Vascular Thrombosis:					
Infection:					
Bleeding:					
Anastomotic Leak:					
Acute Rejection:					
Chronic Rejection:					
Biopsy Proven Isletitis:					
Pancreatitis:					
Patient Noncompliance					
Other, Specify:					
Conv. From Bladder to Enteric Drain Performed: *	YES				
	NO				
	OUNK				
If Yes, Enteric Drainage Date:]			
Most Recent Serum Creatinine:*		mg/dl	ST=		
Pancreas Transplant Complications (Not leading to graft fai	ilure):				
Pancreatitis: *					
Anastomotic Leak: *					
Abscess or Local Infection: *		~			
Other Complications:					
Did patient have any acute rejection episodes during the follow-up period:*	Yes, at least one e	pisode treate	d with anti-r	rejection agent	
	Yes, none treated	with addition	al anti-rejec	tion agent	
	No				
	Unknown				
Viral Detection:					

HIV Serology	Positive
	Negative
	UKN/Cannot Disclose
	ONot Done
HIV NAT	Positive
	Negative
	UKN/Cannot Disclose
	ONot Done
HbsAg	Positive
	ONegative
	UKN/Cannot Disclose
	ONot Done
HBV DNA	Positive
	ONegative
	UKN/Cannot Disclose
	ONot Done
HBV Core Antibody	Positive
	Negative
	UKN/Cannot Disclose
	ONot Done
HCV Serology	Positive
	Negative
	UKN/Cannot Disclose
	ONot Done
HCV NAT	Positive
	ONegative
	UKN/Cannot Disclose
	ONot Done
ost Transplant Malignancy: *	
Donor Related:	
Recurrence of Pre-Tx Tumor:	
De Novo Solid Tumor:	
De Novo Lymphoproliferative disease and Lymphoma:	

Previous Validated Maintenance Follow-Up Medications:	
Previous Validated Maintenance Follow-Up Medications:	
Were any medications given during the follow-up period for maintenance:	○Yes, same as validated TRR form
	ONone given
	\odot Yes, but different than validated TRR form

Immunosuppressive Medications Copyright © 2022 United Network for Organ Sharing. All rights reserved. OPTN use only. 083022

Definitions Of Immunosuppressive Follow-Up Medications

For each of the immunosuppressant medications listed, check **Previous Maintenance (Prev Maint)**, **Current Maintenance (Curr Maint)** or **Anti-rejection** (**AR**) to indicate all medications that were prescribed for the recipient during this follow-up period, and for what reason. If a medication was not given, leave the associated box(es) blank.

Previous Maintenance (Prev Maint) includes all immunosuppressive medications given during the report period, which covers the period from the last clinic visit to the current clinic visit, with the intention to maintain them <u>long-term</u> (example: prednisone, cyclosporine, tacrolimus, mycophenolate mofetil, azathioprine, or Rapamune). This does not include any immunosuppressive medications given to treat rejection episodes.

Current Maintenance (Curr Maint) includes all immunosuppressive medications given at the time of the current clinic visit to begin in the next report period, with the intention to maintain them <u>long-term</u> (example: prednisone, cyclosporine, tacrolimus, mycophenolate mofetil, azathioprine, or Rapamune). This does not include any immunosuppressive medications given to treat rejection episodes.

Anti-rejection (AR) immunosuppression includes all immunosuppressive medications given for the purpose of treating an acute rejection episode since the last clinic visit (example: methylprednisolone or Thymoglobulin). When switching maintenance drugs (example: from tacrolimus to cyclosporine; or from mycophenolate mofetil to azathioprine) because of rejection, the drugs should not be listed under AR immunosuppression, but should be listed under maintenance immunosuppression. >Note: The Anti-rejection field refers to any anti-rejection medications since the last clinic visit, not just at the time of the current clinic visit.

If an immunosuppressive medication other than those listed is being administered (e.g., new monoclonal antibodies), select Previous Maint, or Current Maint, or AR next to Other Immunosuppressive Medication field, and enter the full name of the medication in the space provided. Do not list non-immunosuppressive medications.

Drug used for induction, acute reje	ction, or maintenance			
	Prev Maint	Curr Maint	AR	
Steroids (prednisone, methylprednisolone, Solumedrol, Medrol)				

Drugs used for induction or acute rejection				
	Prev Maint	Curr Maint	AR	
Atgam				
Campath (alemtuzumab)				
Cytoxan (cyclophosphamide)				
Methotrexate (Folex PFS, Mexate- AQ, Rheumatrex)				
Rituxan (rituximab)				
Simulect (basiliximab)				
Thymoglobulin				

Drugs primarily used for maintenance					
	Prev Maint	Curr Maint	AR		
Cyclosporine, select from the following:					
- Gengraf					
- Neoral					
- Sandimmune					
- Generic cyclosporine					
Imuran (azathioprine, AZA)					
Leflunomide (LFL)					
Mycophenolic acid, select from the following:			I		
- CellCept (MMF)					
- Generic MMF (generic CellCept)					
- Myfortic (mycophenolic acid)					
- Generic Myfortic (generic mycophenolic acid)					
mTOR inhibitors, select from the following:					
- Rapamune (sirolimus)					
- Generic sirolimus					
- Zortress (everolimus)					
Nulojix (belatacept)					
Tacrolimus, select from the following:					
- Astagraf XL (extended release tacrolimus)					
- Envarsus XR (tacrolimus XR)					
- Prograf (tacrolimus)					

- Generic tacrolimus (generic Prograf)				
Other drugs				
	Prev Maint	Curr Maint	AR	
Other immunosuppressive medication, specify:				
Other immunosuppressive medication, specify:				

Copyright @ 2022 United Network for Organ Sharing. All rights reserved. Confidential - OPTN Use Only

UNOS Policies & Terms